Research & Development


  • Ira Spector SFA Therapeutics
    Image attribution tooltip
    Permission granted by Ira Spector SFA Therapeutics
    Profile

    A biotech CEO’s favorite ‘F’ word

    At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

    By Jan. 26, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Q&A

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023
  • High angle shot of a group of medical practitioners analyzing x-rays on a digital tablet in a hospital.
    Image attribution tooltip
    Stock via Getty Images

    Report reveals murky picture of clinical trial diversity gains

    Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

    By Alexandra Pecci • Jan. 24, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas
    Q&A

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

    By Jan. 23, 2023
  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX
    Q&A

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

    By Jan. 18, 2023
  • Talia Cohen-Solal Genetika+
    Image attribution tooltip
    Permission granted by Talia Cohen-Solal WoW
    Podcast

    Woman of the Week: Genetika+’s Talia Cohen Solal

    The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

    By Jan. 18, 2023
  • Viewed from above, a rendering of the COVID-19 virus sits in the center of a clay, red basketball court.
    Image attribution tooltip
    Enes Evren via Getty Images
    Profile

    Pro sports’ COVID protocols led to real-world data impacts for pharma

    After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

    By Jan. 16, 2023
  • International Space Station
    Image attribution tooltip
    iStock via Getty Images

    Space — the next frontier in drug development

    Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

    By Kelly Bilodeau • Jan. 12, 2023
  • Claire Aldridge Form Bio
    Image attribution tooltip
    Permission granted by Claire Aldridge Form Bio
    Podcast

    Woman of the Week: Form Bio’s Claire Aldridge

    The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

    By Jan. 11, 2023
  • Hans Schambye Galecto
    Image attribution tooltip
    Permission granted by Hans Schambye
    Q&A // Biotech Spotlight

    Galecto has identified a master switch to reduce fibroid formation

    With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

    By Jan. 11, 2023
  • Kidney
    Image attribution tooltip
    iStock via Getty Images
    Biotech Spotlight

    Chinook Therapeutics nears the finish line in kidney disease

    A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

    By Jan. 10, 2023
  • Karate
    Image attribution tooltip
    grapix via Getty Images

    The kindred nature of martial arts and drug development

    How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

    By Alexandra Pecci • Jan. 9, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Q&A // Biotech Spotlight

    Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

    The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

    By Jan. 9, 2023
  • Alzheimer's road
    Image attribution tooltip
    Cemile Bingol via Getty Images

    Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

    As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

    By Jan. 5, 2023
  • spilled vial
    Image attribution tooltip
    Stock via Getty Images

    Nonprofits are bridging R&D’s valley of death

    How charitable firms such as Advancium are helping to right the market wrongs of drug development.

    By Kelly Bilodeau • Jan. 4, 2023
  • Juliette Han WoW
    Image attribution tooltip
    Permission granted by Juliette Han Cambrian
    Podcast

    Woman of the Week: Cambrian BioPharma’s Juliette Han

    The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

    By Jan. 4, 2023
  • Norman Sussman, chief medical officer, Durect
    Image attribution tooltip
    Permission granted by Durect
    Profile

    Forks in the road lead one medical expert to a ‘game changing’ liver treatment

    Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

    By Alexandra Pecci • Jan. 3, 2023
  • crystal ball 2023
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

    A preview of the top trends on the minds of industry and market leaders for the new year.

    By Jan. 3, 2023
  • A green and yellow pointillism-style painting of a road running through a valley.
    Image attribution tooltip
    Permission granted by Jonathan Douek

    From chemistry to canvas: What the pharma world can learn from art

    Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work. 

    By Dec. 22, 2022
  • Brain MRI scan
    Image attribution tooltip
    iStock via Getty Images

    Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

    New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.

    By Dec. 22, 2022
  • A person in a white lab coat holds an Ipad and pen and sits across from someone gesturing with their hands.
    Image attribution tooltip
    iStock via Getty Images
    Q&A

    To drive trial diversity, one company is bringing them to the patient

    For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.

    By Dec. 21, 2022
  • Signs in florida for a monkeypox vaccine site
    Image attribution tooltip
    Joe Raedle via Getty Images

    With mpox cases mysteriously dwindling, scientists search for answers

    Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.

    By Kelly Bilodeau • Dec. 19, 2022
  • Blood cancer
    Image attribution tooltip
    libre de droit via Getty Images

    Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

    A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.

    By Dec. 19, 2022
  • Stephen Quake, head of science, Chan Zuckerberg Initiative
    Image attribution tooltip
    Permission granted by CZI
    Profile

    How one of the world’s most prolific inventors is guiding a plan to tackle all disease

    Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.

    By Alexandra Pecci • Dec. 15, 2022
  • Vicki Goodwin Exelexis
    Image attribution tooltip
    Permission granted by Exelexis’ Dr. Vicki Goodman
    Podcast

    Woman of the Week: Exelixis’ Dr. Vicki Goodman

    With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

    By Dec. 14, 2022